Browse by author
Lookup NU author(s): Professor Farhad Kamali
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Alza is developing both transdermal and oral (utilizing OROS technology) formulations of the established muscarinic antagonist, oxybutynin, for the treatment of urinary incontinence. The formulations are being developed to improve dosing and reduce side-effects associated with existing formulations of the drug. In December 1997, Alza filed an NDAfor its sustained-release, oncedaily oral formuktion as Ditropan XL 1273067]. This was approved in December 1998 1309867]. US market launch was in early February 1999 1312976]', and Merrill Lynch predicts 1999 revenues to reach $60 million 1300521,10951]. Alza intends to expand the Ditropan line, and plans to introduce a 15 mg tablet by mid-19991314879]. Crescendo has obtained a worldwide license 1309867]. A commercialization agreement for Europe has been made with Synthelabo 1309869]. The product will be filed in Europe during 1999 . Information on the drug can be found on the Internet at www.DitropanXL.com © Current Drugs Ltd.
Author(s): ALZA Corporation, Kamali F
Publication type: Article
Publication status: Published
Print publication date: 01/01/1999
ISSN (print): 1369-7056